OVD

Precision Fermentation Fuels Growth in Ophthalmic Viscoelastic Devices Market: Opportunities and Key Segments - ResearchAndMarkets.com

Retrieved on: 
Friday, September 15, 2023
Surgery, Medical Devices, Health, Pharmaceutical, Optical, Pressure, ASP, Strategic planning, COVID-19, Eye, OVD, Bacteria, Aqueous humour, Hurtigruten AS, Investment, Bioprocess, SWOT analysis, Growth, Meat, Melt, Forecast, Impossible Foods, Retail, Marketing, Telecommunications

This report provides a comprehensive analysis of the Ophthalmic Viscoelastic Devices (OVD) market, highlighting key trends, market dynamics, and valuable insights for stakeholders.

Key Points: 
  • This report provides a comprehensive analysis of the Ophthalmic Viscoelastic Devices (OVD) market, highlighting key trends, market dynamics, and valuable insights for stakeholders.
  • Ophthalmic viscoelastic devices, commonly known as OVDs, play a crucial role in intraocular surgeries.
  • Regional Insights: The Asia Pacific region is expected to register the highest CAGR in the precision fermentation ingredients market.
  • Revenue Growth: Drive revenues by identifying market categories and segments offering maximum opportunities for consolidations, investments, and strategic partnerships.

Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Wednesday, April 26, 2023
Surgery, Medical Devices, Health, Pharmaceutical, Optical, Tradition, Intraocular lens, Aperture, ASCRS, Astigmatism, Pain, Employment, Telecanthus, Incidence, Patient, Outcome, Viral, Steroid, Herpes simplex, NYSE, Chickenpox, Very-small-aperture terminal, Conjunctiva, Cornea, Comparative Effectiveness Research Translation Network, SM, Optic nerve, Cataract, FDA, Emerging technologies, Fungal infection, Refractive surgery, Use, Sclera, Eye, Bausch, History, Thought, American Society of Cataract and Refractive Surgery, Slit lamp, ARMOR, Glaucoma, DED, IOP, Contact lens, Infection, OVD, Inflammation, Vaccinia, Bausch & Lomb, Range, Convention (norm), Visual acuity, Society, Pharmaceutical industry, Telescopic sight, Telescope, Wood drying, Dentistry, Hospital, Retail, Veterinary medicine, Fused quartz, Vaccine, Dietary supplement, Emmetropia, Refraction, IOL

The posters and presentations include two studies assessing the new StableVisc™ cohesive ophthalmic viscosurgical device, which Bausch + Lomb commercially launched this month.

Key Points: 
  • The posters and presentations include two studies assessing the new StableVisc™ cohesive ophthalmic viscosurgical device, which Bausch + Lomb commercially launched this month.
  • Others include a retrospective chart review on the use of LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38% in refractive surgery and numerous presentations focused on Bausch + Lomb surgical IOL pipeline programs.
  • New data from the Bausch + Lomb Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance study will also be presented.
  • “Clinical Evaluation of the Outcomes of Two Preloaded Monofocal IOLs Implanted Bilaterally in Cataract Patients.” Shultz et al.

Bausch + Lomb Announces U.S. Launch of StableVisc™ Cohesive Ophthalmic Viscosurgical Device and TotalVisc™ Viscoelastic System

Retrieved on: 
Monday, April 24, 2023
Science, Biotechnology, Research, Pharmaceutical, Optical, Surgery, Health, Medical Devices, Inflammation, Infection, Tissue, TASS, Allergy, IOP, Cornea, Sodium, Surgeon, Use, Cataract, Eye, Clinical trial, Particulates, OVD, Decompensation, Sale, Direction, Aqueous humour, Intraocular pressure, Bausch & Lomb, Hurtigruten AS, Patient, Phacoemulsification, Freezing, Risk, Cannula, Radical (chemistry), Sorbitol, Paratriathlon, Regulation of tobacco by the U.S. Food and Drug Administration, IOL, NYSE, Posterior cerebral artery, Food, Veterinary medicine, Dentistry, Medical device, Birth control, Pharmaceutical industry, Dry cleaning

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of StableVisc™ cohesive ophthalmic viscosurgical device (OVD) as well as TotalVisc™ Viscoelastic System.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of StableVisc™ cohesive ophthalmic viscosurgical device (OVD) as well as TotalVisc™ Viscoelastic System.
  • TotalVisc Viscoelastic System includes both StableVisc and ClearVisc™, a dispersive OVD, and protects ocular tissue during the surgical procedure.
  • TotalVisc is the only dual pack in the United States that includes a dispersive and cohesive OVD formulated with sorbitol.
  • Federal (USA) law restricts this device to the sale by or on the order of a physician.

Global Retinal Surgery Devices Market Analysis Report 2022-2027: Major Company Profiles, Deals, Strategies, Growth Drivers and Recent Developments - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 28, 2022
Health, Optical, Surgery, Retinal, Diabetes, Therapy, Incidence, Alcon, COVID-19, Epiretinal membrane, FDA, Food, Prevalence, LLC, National Eye Institute, Acquisition, Bausch & Lomb, Compliance, Growth, Center for Urban and Regional Analysis, Retina, Ophthalmology, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, MIGS, OVD, Severe cognitive impairment, Diabetic retinopathy, Vitrectomy, Percussion section, Retinal detachment, Pharmaceutical industry, Dentistry, Health insurance, Medical device, Application, Ivanti

The "Global Retinal Surgery Devices Market (By Device Segment, Application, Regional Analysis), Impact of COVID-19, Company Profiles, Major Deals, Strategy and Recent Developments - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Retinal Surgery Devices Market (By Device Segment, Application, Regional Analysis), Impact of COVID-19, Company Profiles, Major Deals, Strategy and Recent Developments - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • Among the device types, vitrectomy packs segment accounts for the largest revenue share in the global retinal surgery devices market.
  • Vitrectomy machines segment captured second highest share of the global retinal surgery devices market in 2021, being followed by Retinal lasers device segment.
  • Latin America and Middle East and Africa are competing closely to grab maximum share of the retinal surgery devices market.

Gaudio Lab Earns CTA Approval for its OTT Loudness Management Technology

Retrieved on: 
Thursday, September 22, 2022
Online, Car, Adoption, IOS, Electronics, Risk, Consumer Technology Association, LM1, OTT, Association, American National Standards Institute, CTA, Metadata, Growth, Television, TTA, CEO, OVD, Technology, Tank Top TV, Solution, CES, Streaming media, Android, KRX, Mobile phone, Cassette tape

SEOUL, South Korea, Sept. 22, 2022 /PRNewswire/ --Gaudio Lab, a leading audio technology company, today announced that its loudness normalizing technology, 'Loudness Management 1 (LM1)' has been referenced in the standard ANSI/CTA-2075.1 , Loudness Standard for Over the Top Television (OTT) and Online Video Distribution (OVD) for Mobile and Fixed Devices LM1, developed by the Consumer Technology Association (CTA) Video Systems Committee and accredited as an American National Standards.

Key Points: 
  • SEOUL, South Korea, Sept. 22, 2022 /PRNewswire/ --Gaudio Lab, a leading audio technology company, today announced that its loudness normalizing technology, 'Loudness Management 1 (LM1)' has been referenced in the standard ANSI/CTA-2075.1 , Loudness Standard for Over the Top Television (OTT) and Online Video Distribution (OVD) for Mobile and Fixed Devices LM1, developed by the Consumer Technology Association (CTA) Video Systems Committee and accredited as an American National Standards.
  • CTA, North America's largest technology trade association with members from the world's leading innovators from startup to global brands helping support more than 18 million American jobs.
  • "The adoption of the CTA standard signifies that Gaudio Lab's loudness management system is accredited as an audio innovation that can bring forward better sounding experiences to users on a universal level," said Henney Oh, CEO of Gaudio Lab.
  • Gaudio Lab is an audio technology start-up which was founded in 2015, after the company's spatial audio technology for headphones was adopted as the binaural renderer for the ISO/IEC MPEG-H Audio standard in 2014.

Global Cataract Surgery Devices Market Report 2022: Increase in the Prevalence of Cataract Disease & Growth in Incidences of Ocular Disorders Driving Sector - ResearchAndMarkets.com

Retrieved on: 
Friday, September 9, 2022
Optical, Health, Surgery, Medical Devices, Phacoemulsification, Awareness, Hospital, Prevalence, CAGR, OVD, Growth, Coal, Veterinary medicine, IOL

The "Cataract Surgery Devices Market By Product, By Type, By End User: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cataract Surgery Devices Market By Product, By Type, By End User: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
  • An increase in the prevalence of cataract disease, growth in incidences of ocular disorders, as well as technological advancements in ophthalmic devices drives the market.
  • Lack of healthcare insurance and less awareness among individuals regarding the benefits of cataract surgery impede the growth of the cataract surgery devices market.
  • The global cataract surgery devices market is segmented on the basis of product, type, end-user, and region.

Global Ophthalmic Viscoelastic Devices Market Report 2022-2030 Featuring Carl Zeiss Stiftung, Bausch Health Companies, Johnson & Johnson, Alcon, Rayner Intraocular Lenses, & Aurolab - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 11, 2022
Optical, Health, Medical Devices, Hurtigruten AS, Country, ASP, Aqueous humour, Epidemiology, COVID-19, Market access, Phacoemulsification, OVD, SWOT, SWOT analysis, Region, Pressure, Retail, Healthcare, Marketing, Forecast

Ophthalmic Viscoelastic Devices Market Report is built to visualize quantitative market trends within Ophthalmic Devices therapeutic area.

Key Points: 
  • Ophthalmic Viscoelastic Devices Market Report is built to visualize quantitative market trends within Ophthalmic Devices therapeutic area.
  • The model discusses in detail the impact of COVID-19 on Ophthalmic Viscoelastic Devices (OVD) market for the year 2020 and beyond.
  • Ophthalmic viscoelastic devices, also known as OVDs, are devices used during intraocular surgery and are primary composed of sodium hyaluronate, chondroitin sulphate, or hydroxypropyl methylcellulose.
  • SWOT analysis for Ophthalmic Viscoelastic Devices market.

Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical

Retrieved on: 
Thursday, December 23, 2021
Biotechnology, Pharmaceutical, Optical, Surgery, Oncology, Health, Medical Devices, Clinical Trials, Intraocular pressure, U.S. Securities and Exchange Commission, Life, Steroid, Inflammation, Patient, Sale, OVD, Cancer, Atypical hemolytic uremic syndrome, Blood pressure, Visual acuity, Securities Act of 1933, Corporation, Forward-looking statement, SEC, COVID-19, Quality of life, Securities Exchange Act of 1934, IgA nephropathy, Omeros, Immunoglobulin A, IFIS, Incidence, Security (finance), Uveitis, Lead, Phenylephrine, FDA, Telescopic sight, Pharmaceutical industry, IOL, OMIDRIA®, Omeros Corporation, Rayner Surgical Group Limited, OMIDRIA®, OMEROS CORPORATION, RAYNER SURGICAL GROUP LIMITED

Omeros Corporation (Nasdaq: OMER) today announced that it has completed the sale of OMIDRIA (phenylephrine and ketorolac intraocular solution) 1.0%/0.3% to Rayner Surgical Group Inc., an affiliate of Rayner Surgical Group Limited.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced that it has completed the sale of OMIDRIA (phenylephrine and ketorolac intraocular solution) 1.0%/0.3% to Rayner Surgical Group Inc., an affiliate of Rayner Surgical Group Limited.
  • Together with substantial royalties to be paid by Rayner to Omeros on net sales of OMIDRIA, the transaction is valued in excess of $1 billion.
  • Rayner will pay Omeros royalties on both U.S. and ex-U.S. net sales of OMIDRIA.
  • Outside of the U.S., Omeros will receive a 15-percent royalty rate on OMIDRIA net sales throughout the applicable patent life on a country-by-country basis.

Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion

Retrieved on: 
Thursday, December 2, 2021
Biotechnology, Surgery, Health, Pharmaceutical, Optical, Patient, OVD, Blood pressure, Security (finance), Visual acuity, Ophthalmology, Sale, Securities Act of 1933, Cancer, IgA nephropathy, Forward-looking statement, Immunoglobulin A, Surgeon, Steroid, Inflammation, SEC, Hart–Scott–Rodino Antitrust Improvements Act, U.S. Securities and Exchange Commission, COVID-19, Uveitis, Securities Exchange Act of 1934, Corporation, IFIS, Incidence, EMA, FDA, Phenylephrine, Intraocular pressure, Atypical hemolytic uremic syndrome, Internet, Life, Growth, Quality of life, Pharmaceutical industry, Telescopic sight, OMIDRIA®, Omeros Corporation, Rayner Surgical Group Limited, OMIDRIA®, OMEROS CORPORATION, RAYNER SURGICAL GROUP LIMITED

Omeros Corporation (Nasdaq: OMER) today announced that it has entered into a definitive agreement for the sale of OMIDRIA to Rayner Surgical Group Limited.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced that it has entered into a definitive agreement for the sale of OMIDRIA to Rayner Surgical Group Limited.
  • Together with substantial royalties to be paid by Rayner to Omeros on net sales of OMIDRIA, the transaction is valued in excess of $1 billion.
  • OMIDRIA will become a key product in Rayners ophthalmology franchise, which includes intraocular lenses, ophthalmic viscoelastic devices and dry eye treatments.
  • As part of the agreement, Rayner will acquire the OMIDRIA commercial organization, including the OMIDRIA sales force.

OpSec Security invests in Europe’s first HP Indigo 6K Secure Digital Press

Retrieved on: 
Tuesday, November 16, 2021
HP, Industry, CEO, Optically variable ink, Technology, Secure, Operations security, OVD, Insight, Digital, Marketing strategy, Partnership, HP Indigo Division, GLOBE, Solution, Security printing

CROWTHER, United Kingdom, Nov. 16, 2021 (GLOBE NEWSWIRE) -- OpSec Security , a world leader in security and brand protection, has invested in Europes first HP Indigo 6K Secure Digital Press.

Key Points: 
  • CROWTHER, United Kingdom, Nov. 16, 2021 (GLOBE NEWSWIRE) -- OpSec Security , a world leader in security and brand protection, has invested in Europes first HP Indigo 6K Secure Digital Press.
  • The single-pass capability and secure variable data options of the HP Indigo 6K Secure Digital Press will increase further the options available to its customers.
  • We are excited to welcome OpSec Security as the first customer of the HP Indigo 6K Secure Press in Europe.
  • From electroinks to variable data options and multi-layered secure print features, the HP Indigo 6K Secure Digital Press presented OpSec with a compelling, world-leading integrated hardware and software solution.